scholarly journals Anti-Tumor Effects of Exosomes Derived from Drug-Incubated Permanently Growing Human MSC

2020 ◽  
Vol 21 (19) ◽  
pp. 7311 ◽  
Author(s):  
Catharina Melzer ◽  
Juliane von der Ohe ◽  
Ralf Hass
Keyword(s):  
Breast Cancer ◽  
Cancer Cell ◽  
Cell Cultures ◽  
Large Scale ◽  
Primary Cultures ◽  
Cancer Model ◽  
Oral Gavage ◽  
Cytotoxic Effects ◽  
Breast Cancer Model

Similar to growth-limited human primary cultures of mesenchymal stroma/stem-like cells (MSC), the continuously proliferating human MSC544 cell line produced extracellular vesicles as characterized by expression of the tetraspanin molecules CD9, CD63, and CD81. Release of these particles was predominantly detectable during continuous cell growth of MSC544 in contrast to confluency-mediated transient growth arrest. For therapeutic use, these particles were isolated from proliferating MSC544 after taxol treatment and applied to different cancer cell cultures. A pronounced cytotoxicity of lung, ovarian, and breast cancer cells was observed primarily with taxol-loaded exosomes, similar to the effects displayed by application of taxol substance. While these findings suggested pronounced cancer cell targeting of MSC544 exosomes, a tumor therapeutic approach was performed using a mouse in vivo breast cancer model. Thus, intravenous injection of taxol-loaded MSC544 exosomes displayed superior tumor-reducing capabilities as compared to application of taxol exosomes by oral gavage. To broaden this therapeutic spectrum, epirubicin was applied to MSC544, and the derived exosomes likewise exhibited significant cytotoxic effects in different cancer cell cultures. These findings suggest an unlimited source for large-scale exosome production with reproducible quality to enable variable drug targeting of tumors or other diseases.

Therapeutic monoclonal antibodies target phenotypically-differing human breast cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 13510-13510
Author(s):  
S. E. Hahn ◽  
L. A. da Cruz ◽  
D. Sayegh ◽  
A. Ferry ◽  
K. O’Reilly ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
In Vivo Studies ◽  
Tumor Growth Inhibition ◽  
Cancer Model ◽  
Human Breast ◽  
Breast Cancer Model ◽  
Cancer Tissues

13510 Background: CD44 (an adhesion molecule and stem cell antigen), CD59 (a complement-inhibitory molecule), MCSP (an adhesion and cell-cell interactions), and Trop-2 (EpCam a related signaling molecule) represent a group of biologically-significant cancer proteins acting through distinct mechanisms. We have described Abs with in vitro and in vivo cancer suppressive activity to this group of targets. However, their effectiveness depends on the phenotype of malignant cells; cell response should correlate with expression of its Ag, and tumor cells represent a heterogeneous group of non-synchronous cells. The present study describes the efficacy of those antibodies in breast cancer models and the prevalence of their antigen targets in a survey of human breast cancer tissues. Methods: In vivo activity of antibodies ARH460–16–2 (anti-CD44), AR36A36.11.1 (anti-CD59), AR11BD-2E11–2 (anti-MCSP), and AR47A6.4.2 (anti-Trop-2) in estrogen-dependent and hormone sensitive xenograft models of human breast cancer was examined. In addition, distribution of the antigens in breast cancer was determined by immunohistochemistry using tumor tissue arrays of breast cancer sections from distinct patients. Results: Treatment of an established breast cancer model with ARH460–16–2 resulted in 51% median tumor xenograft suppression (p<0.05), as well as increased survival in an MDA-MB-231 (breast cancer) grafted model. 63% of human breast cancer sections expressed the CD44 antigen. Treatment with anti-CD59 antibody AR36A36.11.1 resulted in 68% xenograft tumor suppression (p<0.005). AR47A6.4.2 anti-Trop-2 antibody bound to 100% of human breast cancer sections tested, and showed efficacy in the estrogen- dependent MCF-7 breast cancer model. Anti-MCSP antibody AR11BD-2E11–2 demonstrated 80% tumor growth inhibition (p<0.001), increased survival in an estrogen-dependent model of breast cancer, and was found to stain 62% of breast cancer tissues examined. Conclusions: The heterogeneity of breast cancer cell phenotypes in in vitro and in vivo studies and variable composite cellular antigen targets is the basis for the therapeutic use of multiple antibodies, each with independent mechanisms of action, and offers a rationale for combined antibody therapy in selected patients. [Table: see text]

scholarly journals In Vivo Lymphatic Imaging of a Human Inflammatory Breast Cancer Model

2014 ◽  
Vol 5 (9) ◽  
pp. 774-783 ◽  
Author(s):  
Germaine D. Agollah ◽  
Grace Wu ◽  
Eva M. Sevick-Muraca ◽  
Sunkuk Kwon
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Lymphatic Imaging

Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model

2014 ◽  
Vol 349 (2) ◽  
pp. 120-127 ◽  
Author(s):  
Lucia Borriello ◽  
Matthieu Montès ◽  
Yves Lepelletier ◽  
Bertrand Leforban ◽  
Wang-Qing Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Anti Tumor Activity

scholarly journals Eupatorin Suppressed Tumor Progression and Enhanced Immunity in a 4T1 Murine Breast Cancer Model

2020 ◽  
Vol 19 ◽  
pp. 153473542093562
Author(s):  
Nursyamirah Abd Razak ◽  
Swee Keong Yeap ◽  
Noorjahan Banu Alitheen ◽  
Wan Yong Ho ◽  
Chean Yeah Yong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Development ◽  
Interferon Γ ◽  
Mice Model ◽  
Cytotoxic Effects ◽  
Breast Cancer Model ◽  
Tnf Α ◽  
4T1 Cells ◽  
Cancer Agent

Eupatorin is a polymethoxy flavone extracted from Orthosiphon stamineus and was reported to exhibit cytotoxic effects on several cancer cell lines. However, its effect as an anti–breast cancer agent in vivo has yet to be determined. This study aims to elucidate the potential of eupatorin as an anti–breast cancer agent in vivo using 4T1 challenged BALB/c mice model. In this article, BALB/c mice (20-22 g) challenged with 4T1 cells were treated with 5 mg/kg or 20 mg/kg eupatorin, while the untreated and healthy mice were fed with olive oil (vehicle) via oral gavage. After 28 days of experiment, the mice were sacrificed and blood was collected for serum cytokine assay, while tumors were harvested to extract RNA and protein for gene expression assay and hematoxylin-eosin staining. Organs such as spleen and lung were harvested for immune suppression and clonogenic assay, respectively. Eupatorin (20 mg/kg) was effective in delaying the tumor development and reducing metastasis to the lung compared with the untreated mice. Eupatorin (20 mg/kg) also enhanced the immunity as the population of NK1.1+ and CD8+ in the splenocytes and the serum interferon-γ were increased. Concurrently, eupatorin treatment also has downregulated the expression of pro-inflammatory and metastatic related genes (IL-1β. MMP9, TNF-α, and NF-κB). Thus, this study demonstrated that eupatorin at the highest dosage of 20 mg/kg body weight was effective in delaying the 4T1-induced breast tumor growth in the animal model.

In vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic 1 Triple Negative Breast Cancer Model

2016 ◽  
Vol 16 (999) ◽  
pp. 1-1 ◽  
Author(s):  
Nuno Mendes ◽  
Francisco Tortosa ◽  
Andreia Valente ◽  
Fernanda Marques ◽  
António Matos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Cancer Model ◽  
Breast Cancer Model

Abstract 4606: An in vitro and in vivo evaluation of novel anticancer agents in a triple negative breast cancer model

2010 ◽  
Author(s):  
Tamorah Hawthorne ◽  
Joseph Gallien ◽  
Lee Gibbs ◽  
Janeque Jones ◽  
Shannon Muir ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Anticancer Agents ◽  
Triple Negative ◽  
Cancer Model ◽  
In Vivo Evaluation ◽  
Breast Cancer Model

In vivo optoacoustic monitoring of percutaneous laser ablation of tumors in a murine breast cancer model

2020 ◽  
Vol 45 (7) ◽  
pp. 2006
Author(s):  
Vijitha Periyasamy ◽  
Çağla Özsoy ◽  
Michael Reiss ◽  
Xosé Luís Deán-Ben ◽  
Daniel Razansky
Keyword(s):  
Breast Cancer ◽  
Laser Ablation ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Percutaneous Laser Ablation

In vivo detection of distal tumor glycolytic flux stimulated by hepatic ablation in a breast cancer model using hyperpolarized 13C MRI

2021 ◽  
Author(s):  
J. Scott Goodwin ◽  
Leo L. Tsai ◽  
David Mwin ◽  
Patricia Coutinho de Souza ◽  
Svayam Dialani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Glycolytic Flux ◽  
Cancer Model ◽  
Hyperpolarized 13C ◽  
In Vivo Detection ◽  
Distal Tumor ◽  
Breast Cancer Model ◽  
Hepatic Ablation
Sign in / Sign up

Export Citation Format

Share Document